Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Seagen Inc.

< Previous 1 2 3 Next >
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers MRK SGEN
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Names David R. Epstein as Chief Executive Officer and Director
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports Third Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
From Seagen Inc.
Via Business Wire
Tickers SGEN ZLAB
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
From Seagen Inc.
Via Business Wire
Tickers LVTX SGEN
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers MRK SGEN
Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports Second Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers GMAB SGEN
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Reports First Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seagen Inc.
Via Business Wire
Tickers SGEN
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
From Seagen Inc.
Via Business Wire
Tickers SGEN
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.